| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA043623 |
| P698 | PubMed publication ID | 15972865 |
| P50 | author | Ming-Sound Tsao | Q47492209 |
| Eric Vallieres | Q58328869 | ||
| National Cancer Institute of Canada Clinical Trials Group | Q60557915 | ||
| David R Gandara | Q73567194 | ||
| Yvon Cormier | Q75045348 | ||
| P2093 | author name string | David Johnson | |
| Frances Shepherd | |||
| Lesley Seymour | |||
| Michael Johnston | |||
| Joseph Ayoub | |||
| Barbara Graham | |||
| Charles Butts | |||
| Drew Bethune | |||
| Glenwood Goss | |||
| James Rigas | |||
| Kenneth Kesler | |||
| Keyue Ding | |||
| National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators | |||
| Richard Inculet | |||
| Robert Livingston | |||
| Timothy Winton | |||
| Todd Demmy | |||
| Willard Fry | |||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| cisplatin | Q412415 | ||
| P304 | page(s) | 2589-2597 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer | |
| P478 | volume | 352 |
| Q64235323 | Q64235323 |
| Q27002509 | 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer |
| Q38190426 | 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up |
| Q27014978 | 50 Years of progress in the systemic therapy of non-small cell lung cancer |
| Q36746536 | A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients |
| Q35804931 | A Panel of Genetic Polymorphism for the Prediction of Prognosis in Patients with Early Stage Non-Small Cell Lung Cancer after Surgical Resection |
| Q92237983 | A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer |
| Q30742035 | A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy |
| Q37724940 | A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer |
| Q42122499 | A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients |
| Q34747013 | A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial |
| Q28267987 | A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer: implications for adjuvant therapy |
| Q37682246 | A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer |
| Q36111869 | A decade of advances in treatment of early-stage lung cancer |
| Q33974932 | A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma |
| Q34555834 | A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. |
| Q98210237 | A network meta-analysis: The best Yiqi Fuzheng Chinese herbal injections for use based on the NP regimen to treat NSCLC |
| Q34074425 | A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). |
| Q47715936 | A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer |
| Q37023671 | A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer |
| Q30539299 | A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer |
| Q35803022 | A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies |
| Q38292389 | A proposal of postoperative follow-up pathways for lung cancer |
| Q36882714 | A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204) |
| Q41718710 | A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial |
| Q45949842 | A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. |
| Q37415161 | A simple two-gene prognostic model for adenocarcinoma of the lung |
| Q38976630 | A small molecule that induces reactive oxygen species via cellular glutathione depletion |
| Q42690847 | A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice |
| Q36382373 | ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer |
| Q33786162 | ATS Core Curriculum 2014: part I. Adult pulmonary medicine |
| Q21092374 | Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer |
| Q35939945 | Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer |
| Q83995222 | Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells |
| Q50918375 | Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. |
| Q43271608 | Actual status of adjuvant chemotherapy for non-small-cell lung cancer at one Japanese cancer center: the need for increased cooperation between medical oncologists and surgeons |
| Q37729195 | Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. |
| Q41554812 | Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial. |
| Q36654156 | Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported? |
| Q39692515 | Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC |
| Q34479081 | Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| Q90092841 | Adjuvant Chemotherapy with Chinese Herbal Medicine Formulas Versus Placebo in Patients with Lung Adenocarcinoma after Radical Surgery: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial |
| Q90029265 | Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis |
| Q35584223 | Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions |
| Q38831491 | Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward? |
| Q36430299 | Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift |
| Q55080685 | Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era? |
| Q37228519 | Adjuvant chemotherapy after complete resection of non-small cell lung cancer |
| Q35290702 | Adjuvant chemotherapy after resection of N1 non-small cell lung cancer: differential impact of new evidence on physician and patient decisions |
| Q37217748 | Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC) |
| Q36419436 | Adjuvant chemotherapy and targeted therapy in elderly non-small-cell lung cancer patients |
| Q35971726 | Adjuvant chemotherapy for early stage non-small cell lung cancer |
| Q36521844 | Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future |
| Q37270934 | Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. |
| Q40173367 | Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis |
| Q81605206 | Adjuvant chemotherapy for non-small cell lung cancer |
| Q40340183 | Adjuvant chemotherapy for non-small cell lung cancer: the new standard of care |
| Q34143336 | Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? |
| Q24187439 | Adjuvant chemotherapy for resected early-stage non-small cell lung cancer |
| Q36780586 | Adjuvant chemotherapy for resected non-small cell lung cancer. |
| Q80198221 | Adjuvant chemotherapy for resected non-small-cell lung cancer--ANITA takes the stage |
| Q35771994 | Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research |
| Q36715269 | Adjuvant chemotherapy in elderly patients with non-small-cell lung cancer |
| Q38419828 | Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art |
| Q35200745 | Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer |
| Q37185492 | Adjuvant chemotherapy in resected lung cancer: two-year experience in a university hospital |
| Q35200660 | Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). |
| Q34126484 | Adjuvant chemotherapy of non-small cell lung cancer |
| Q33698361 | Adjuvant chemotherapy of non-small-cell lung cancer |
| Q47219768 | Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial |
| Q33546241 | Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data |
| Q37777311 | Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all? |
| Q30438068 | Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups |
| Q39012785 | Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). |
| Q37404376 | Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung |
| Q83908693 | Adjuvant therapy for non-small-cell lung cancer |
| Q35076202 | Adjuvant therapy for resected non-small cell lung cancer |
| Q87949870 | Adjuvant vinorelbine and cisplatin after complete resection of stage II and III non-small cell lung cancer: long-term follow-up of our study of Japanese patients |
| Q33999146 | Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial |
| Q34048802 | Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study |
| Q34031225 | Advances in adjuvant systemic therapy for non-small-cell lung cancer |
| Q44305758 | American Thoracic Society Annual International Congress |
| Q33241239 | Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer |
| Q37699284 | An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer |
| Q37137440 | An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC). |
| Q38109229 | An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment |
| Q46704388 | Antitumor activity of noscapine in human non-small cell lung cancer xenograft model |
| Q36413281 | Antrodia cinnamomea alleviates cisplatin-induced hepatotoxicity and enhances chemo-sensitivity of line-1 lung carcinoma xenografted in BALB/cByJ mice. |
| Q37500880 | Application of cancer genomics to solve unmet clinical needs. |
| Q53337649 | Are we coming full circle for lung cancer screening a second time? |
| Q35200402 | Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer? |
| Q40915441 | Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma. |
| Q54096708 | Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer. |
| Q40394915 | Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery |
| Q99560518 | Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features |
| Q49256406 | Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer |
| Q34978347 | Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients |
| Q36832129 | Bevacizumab in the treatment of non-small-cell lung cancer |
| Q46834505 | Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC) |
| Q37342919 | Biomarkers in lung cancer: from early detection to novel therapeutics and decision making |
| Q51743346 | Burden of chemotherapy-induced neuropathy--a cross-sectional study. |
| Q58287522 | CANADIAN CANCER RISK MANAGEMENT MODEL: EVALUATION OF CANCER CONTROL |
| Q89985645 | CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in Stage I, II resectable Non-Small Cell Lung Cancer: a retrospective multi-cohort study for outcome prediction |
| Q30439235 | CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer |
| Q46790766 | Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer? |
| Q38785343 | Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study |
| Q28265589 | Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer |
| Q41090595 | Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up |
| Q36225309 | Carcinoma of the bronchus 60 years later |
| Q34538974 | Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy |
| Q90586446 | Characterization of Dyspnea in Veteran Lung Cancer Survivors Following Curative-Intent Therapy |
| Q38999884 | Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing. |
| Q36989648 | Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer |
| Q80420032 | Chemotherapy and surgery for operable NSCLC |
| Q37614566 | Chemotherapy for lung cancer: the state of the art in 2009. |
| Q37524918 | Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy |
| Q38838014 | Chemotherapy remains an essential element of personalized care for persons with lung cancers |
| Q36278580 | Chemotherapy uptake and wait times in early-stage non-small-cell lung cancer |
| Q37800603 | Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC |
| Q43058277 | Chemotherapy-induced peripheral neuropathy: an unresolved issue |
| Q37395888 | Cisplatin versus carboplatin in NSCLC: is there one "best" answer? |
| Q36064193 | Clinical Characteristics of Resected T3 Non-small Cell Lung Cancer Characterized by Parietal Pleural Invasion or Chest Wall Invasion |
| Q39328954 | Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma |
| Q37090628 | Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer |
| Q39321608 | Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma |
| Q53350126 | Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. |
| Q37750786 | Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers |
| Q36785118 | Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung |
| Q51022866 | Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. |
| Q92968499 | Comparing the benefits of postoperative adjuvant chemotherapy vs. observation for stage IB non-small cell lung cancer: a meta-analysis |
| Q38118480 | Comparison of different adjuvant therapies for 9 resectable cancer types |
| Q38696794 | Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience |
| Q92859970 | Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma |
| Q36545344 | Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy |
| Q38176433 | Controversies in the management of stage III non-small-cell lung cancer |
| Q37338248 | Controversies in the management of stage IIIA non-small-cell lung cancer |
| Q35605711 | Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective |
| Q36558386 | Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer |
| Q33577838 | Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer |
| Q37244584 | Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA. |
| Q35747285 | Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials |
| Q39999691 | Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer |
| Q52715754 | Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. |
| Q35096604 | Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy |
| Q37187893 | Decision-making by surgeons about referral for adjuvant therapy for patients with non-small-cell lung, breast or colorectal cancer: a qualitative study |
| Q60723286 | Decrease in the vinorelbine-induced venous irritation by pharmaceutical intervention |
| Q35752182 | Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing. |
| Q36617872 | Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer |
| Q92457998 | Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits |
| Q34408058 | Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells |
| Q44901755 | Detection of novel paraja ring finger 2-fer tyrosine kinase mRNA chimeras is associated with poor postoperative prognosis in non-small cell lung cancer |
| Q41857918 | Diagnosis, staging and treatment of patients with non-small cell lung cancer for the surgeon. |
| Q64083848 | Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis |
| Q89287981 | Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma |
| Q35106784 | Differential prognostic significance of extralobar and intralobar nodal metastases in patients with surgically resected stage II non-small cell lung cancer |
| Q39117932 | Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification |
| Q37815607 | Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma |
| Q37634419 | Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma |
| Q35813748 | Dysregulation of PAK1 Is Associated with DNA Damage and Is of Prognostic Importance in Primary Esophageal Small Cell Carcinoma |
| Q34782417 | EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation |
| Q37589341 | EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. |
| Q34357698 | ERCC1 and personalized medicine in lung cancer |
| Q30580553 | ERCC1 isoform expression and DNA repair in non-small-cell lung cancer |
| Q45794075 | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q89400755 | Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection |
| Q59274190 | Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q37696112 | Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma |
| Q49742077 | Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model |
| Q41073858 | Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer. |
| Q52758452 | Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer. |
| Q33594314 | Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients |
| Q55096365 | Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study. |
| Q53527634 | Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings. |
| Q37362867 | Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4. |
| Q36934628 | Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer |
| Q33798819 | Efficacy of postoperative radiotherapy in patients with pathological stage N2 epidermal growth factor receptor wild type adenocarcinoma and squamous cell carcinoma lung cancer |
| Q54577822 | Endogenous secretory receptor for advanced glycation end products in non-small cell lung carcinoma. |
| Q42353390 | Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions |
| Q36443643 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer |
| Q38906773 | Epidermal Growth Factor Receptor Mutation Status and Treatment Outcome for R0-Resected Patients with Stage 3 Non-small Cell Lung Cancer |
| Q91739038 | Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stages II-III |
| Q37754925 | Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment |
| Q33620462 | Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study |
| Q94373214 | Evolution of thoracic surgery in Canada |
| Q41900593 | Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. |
| Q37592133 | Excitatory Hindbrain-Forebrain Communication Is Required for Cisplatin-Induced Anorexia and Weight Loss. |
| Q41603225 | Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. |
| Q24604495 | Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses |
| Q37060376 | Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non-small cell lung cancer in a single center |
| Q36931100 | Explorations of lung cancer stigma for female long-term survivors |
| Q42400026 | Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer |
| Q92579583 | Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancer |
| Q36244183 | Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane |
| Q37665660 | Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions |
| Q36416218 | Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma |
| Q33289240 | External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer |
| Q61043422 | Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer |
| Q36568563 | Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study |
| Q48128817 | Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer |
| Q37643536 | Fatigue in lung cancer patients: symptom burden and management of challenges |
| Q35667757 | Feasibility Of Administering Adjuvant Chemotherapy Of Pemetrexed Followed By Pemetrexed/oxaliplatin Immediately Post-VATS In Patients With Completely Resected NSCLC |
| Q33437409 | Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001. |
| Q33408830 | Feasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected non-small cell lung cancer |
| Q37081978 | Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0 |
| Q46735765 | Feasibility trial of adjuvant chemotherapy with paclitaxel and carboplatin after surgical resection in Japanese patients with non-small cell lung cancer: report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0501. |
| Q27851448 | Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma |
| Q35156166 | Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing |
| Q102210881 | Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis |
| Q36381261 | Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer? |
| Q40423319 | Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm. |
| Q33812904 | Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer |
| Q34146519 | Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients |
| Q62785321 | Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer |
| Q53024964 | Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep sequencing. |
| Q34322495 | Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer |
| Q37004642 | Genomic signatures individualize therapeutic decisions in non-small-cell lung cancer |
| Q36774403 | Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer |
| Q42384649 | Has lobe-specific nodal dissection for early-stage non-small lung cancer already become standard treatment? |
| Q35111780 | Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials |
| Q38065082 | Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer |
| Q34956692 | High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients |
| Q36288148 | High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications |
| Q33877902 | Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). |
| Q33815687 | Histone variant H3F3A promotes lung cancer cell migration through intronic regulation |
| Q35146944 | How close are we to customizing chemotherapy in early non-small cell lung cancer? |
| Q36416460 | How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study |
| Q37575617 | How is gene-expression profiling going to challenge the future management of lung cancer? |
| Q46743460 | How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study |
| Q84880388 | Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer |
| Q36753922 | Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer |
| Q35811159 | Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing |
| Q89511647 | Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis |
| Q37335929 | Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. |
| Q36049618 | Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. |
| Q90711347 | Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10 |
| Q52624364 | Immunotherapy in surgically resectable non-small cell lung cancer. |
| Q36058277 | Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans |
| Q37742492 | Impact of biomarkers on non-small cell lung cancer treatment |
| Q38622807 | Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection |
| Q43485864 | Impact of main bronchial lymph node involvement in pathological T1-2N1M0 non-small-cell lung cancer: multi-institutional survey by the Japan National Hospital Study Group for Lung Cancer |
| Q33684103 | Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma. |
| Q36916714 | Impact of smoking status on the biological behavior of lung cancer |
| Q48627805 | Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer |
| Q36197030 | Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer |
| Q37186795 | Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations |
| Q43197895 | Improved compliance with adjuvant vinorelbine and cisplatin in non-small cell lung cancer |
| Q42384614 | Improving post-resection risk stratification in non-small cell lung cancer: 'wit, whither wander you?' |
| Q36416261 | Improving referral of patients for consideration of adjuvant chemotherapy after surgical resection of lung cancer |
| Q35996033 | Improving the pathologic evaluation of lung cancer resection specimens |
| Q33554024 | Increasing access to medical oncology consultation in older patients with stage II-IIIA non-small-cell lung cancer |
| Q43065749 | Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma |
| Q37407906 | Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: current status and future directions |
| Q37478345 | Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer |
| Q46090770 | Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer |
| Q30487266 | Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer |
| Q41656021 | Intratracheal Administration of Hyaluronan-Cisplatin Conjugate Nanoparticles Significantly Attenuates Lung Cancer Growth in Mice. |
| Q53289279 | Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer |
| Q37073084 | Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? |
| Q33871917 | Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer? |
| Q42948379 | K-RAS gene mutations in patients with non-small cell lung cancer |
| Q26829425 | K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value |
| Q37789445 | KRAS gene mutations in lung cancer: Particulars established and issues unresolved |
| Q37067360 | KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma |
| Q34627201 | Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer |
| Q34430511 | L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review |
| Q51815597 | Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. |
| Q47602301 | Long-Term and Latent Side Effects of Specific Cancer Types |
| Q35923256 | Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis |
| Q33759505 | Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage IA non-small cell lung cancer |
| Q36931849 | Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology |
| Q38830349 | Lung Cancer Staging and Prognosis. |
| Q30235908 | Lung cancer in Brazil: epidemiology and treatment challenges |
| Q36328370 | Lung cancer: Biology and treatment options |
| Q46049056 | Lung cancer: New biological insights and recent therapeutic advances |
| Q38211457 | Lymph node dissection for lung cancer: past, present, and future |
| Q38815555 | Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis |
| Q37798621 | Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer |
| Q34783070 | Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know? |
| Q88149109 | Management of Lung Cancer in the Elderly |
| Q53929386 | Management of early-stage non-small-cell lung cancer (NSCLC). |
| Q37171914 | Mass spectrometry-based proteomic profiling of lung cancer |
| Q36920148 | Measuring health-related quality of life in drug clinical trials: is it given due importance? |
| Q26859343 | Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysis |
| Q55208721 | Meet the new boss: lung cancer staging. |
| Q44603884 | Meeting highlights of the European Respiratory Society annual congress 02-06 September 2006, Munich, Germany |
| Q35934898 | Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer |
| Q30976026 | Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data |
| Q46817134 | Metastasis: From head to tail |
| Q39027918 | Metastatic signature in lung cancer is associated with sensitivity to anti-integrin α(V) monoclonal antibody intetumumab |
| Q35224272 | Metformin inhibits the proliferation of A549/CDDP cells by activating p38 mitogen-activated protein kinase |
| Q35738706 | MicroRNA as tools and therapeutics in lung cancer |
| Q34268278 | MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma |
| Q39214395 | Milestones in the systemic treatment of lung cancer |
| Q89622199 | Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer |
| Q40717001 | Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non-Small Cell Lung Cancer |
| Q37347532 | Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy |
| Q36795140 | Molecular pharmacokinetics of catharanthus (vinca) alkaloids |
| Q55159440 | Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts. |
| Q37606747 | Molecular predictive and prognostic markers in non-small-cell lung cancer. |
| Q44582343 | Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms |
| Q37771888 | Molecular testing in lung cancer: the time is now. |
| Q30430515 | Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer |
| Q36905245 | Multimodality approach to early-stage non-small cell lung cancer |
| Q35995409 | Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancer |
| Q35632096 | NRSN2 promotes non-small cell lung cancer cell growth through PI3K/Akt/mTOR pathway |
| Q37486185 | NSCLC in the elderly--the legacy of therapeutic neglect |
| Q89585672 | Neoadjuvant versus adjuvant chemotherapy for resectable non-small cell lung cancer debate revisited |
| Q37225293 | Nitrilase 1 modulates lung tumor progression in vitro and in vivo. |
| Q33913885 | Nomograms for predicting progression and efficacy of post-operation radiotherapy in IIIA-pN2 non-small cell lung cancer patients |
| Q40288879 | Non small cell lung cancer - comparison between clinical and pathological staging |
| Q37240128 | Non-small cell lung cancer in the elderly: defining treatment options |
| Q36835919 | Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy |
| Q28278682 | Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship |
| Q36463948 | Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond |
| Q37874768 | Non-small-cell lung cancer. |
| Q33909660 | Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. |
| Q42914705 | Non–Small-Cell Lung Cancer mRNA Expression Signature Predicting Response to Adjuvant Chemotherapy |
| Q97539276 | Novel treatment strategies for early-stage lung cancer: the oncologist's perspective |
| Q37624787 | Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non-small cell lung cancer |
| Q52928581 | Operative outcomes of thoracoscopic lobectomy for non-small-cell lung cancer. |
| Q37121482 | Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer |
| Q58699992 | Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses |
| Q55438459 | Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. |
| Q92983835 | Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis |
| Q52905200 | Outcomes of initial surgery in patients with clinical N2 non-small cell lung cancer who met 4 specific criteria. |
| Q36596567 | Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer |
| Q57074286 | PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study |
| Q36923447 | Pathologic correlation of serum carcinoembryonic antigen and cytokeratin 19 fragment in resected nonsmall cell lung cancer |
| Q36525431 | Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint |
| Q36924273 | Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity? |
| Q35537982 | Patterns of dynamic hyperinflation during exercise and recovery in patients with severe chronic obstructive pulmonary disease |
| Q35003631 | Pemetrexed for the treatment of non-small-cell lung cancer |
| Q33429178 | Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer |
| Q54373981 | Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. |
| Q37797818 | Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy? |
| Q38400481 | Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors |
| Q43061648 | Perspectives in adjuvant chemotherapy in NSCLC. |
| Q38386745 | Pharmacotherapy for treatment of lung cancer in the elderly |
| Q64377929 | Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer |
| Q46125340 | Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer. |
| Q33391435 | Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial |
| Q37346454 | Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers |
| Q50109053 | Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer |
| Q80494703 | Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer |
| Q34314653 | Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. |
| Q43937565 | Phase III randomised trial of adjuvant chemotherapy with cisplatin plus docetaxel versus cisplatin plus gemcitabine in resected non-small cell bronchial carcinoma with quality of life as the primary objective |
| Q92851498 | Phosphoserine Phosphatase Promotes Lung Cancer Progression through the Dephosphorylation of IRS-1 and a Noncanonical L-Serine-Independent Pathway |
| Q54106023 | Physician Agency and Patient Survival. |
| Q60445024 | Place des traitements adjuvants et néo-adjuvants dans les cancers non à petites cellules (CBNPC) de stade précoce |
| Q37695838 | Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung |
| Q51029938 | Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. |
| Q27313799 | Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy |
| Q89450297 | Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients |
| Q26830376 | Post-operative radiation therapy |
| Q37456466 | Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer |
| Q36543892 | Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy |
| Q42700696 | Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma |
| Q35584905 | Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution |
| Q30868582 | Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base |
| Q37364511 | Predicting recurrence using the clinical factors of patients with non-small cell lung cancer after curative resection |
| Q35687989 | Prediction of Clinical Outcome for All Stages and Multiple Cell Types of Non-small Cell Lung Cancer in Five Countries Using Lung Cancer Prognostic Index |
| Q28743108 | Predictive and prognostic molecular markers for cancer medicine |
| Q41067049 | Predictors of post-recurrence survival in patients with non-small-cell lung cancer initially completely resected |
| Q31036733 | Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base |
| Q36682970 | Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes |
| Q36915205 | Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer |
| Q64246128 | Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer |
| Q38390072 | Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures |
| Q43026297 | Prognostic and predictive biomarkers post curative intent therapy |
| Q38089884 | Prognostic and predictive factors in resected non-small-cell lung cancer |
| Q30497419 | Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer |
| Q38019976 | Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer |
| Q28394974 | Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer |
| Q37996270 | Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer |
| Q30498101 | Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer |
| Q51072307 | Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer. |
| Q54632156 | Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. |
| Q44910232 | Prognostic factors for disease-free survival in pT2N0 non-small cell lung cancer |
| Q34610099 | Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy |
| Q46634553 | Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. |
| Q89822615 | Prognostic factors in operated T3 non-small cell lung cancer: A retrospective, single-center study of 129 patients |
| Q35634785 | Prognostic factors of resected node-positive lung cancer: location, extent of nodal metastases, and multimodal treatment |
| Q36929742 | Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer |
| Q30485836 | Prognostic gene signatures for non-small-cell lung cancer |
| Q44237850 | Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer |
| Q35200555 | Prognostic markers in lung cancer: is it ready for prime time? |
| Q36156142 | Prognostic nutritional index before adjuvant chemotherapy predicts chemotherapy compliance and survival among patients with non-small-cell lung cancer |
| Q40978136 | Prognostic significance of ABCB1 in stage I lung adenocarcinoma |
| Q90475240 | Prognostic significance of IMMT expression in surgically-resected lung adenocarcinoma |
| Q34775815 | Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma |
| Q53248377 | Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. |
| Q39693900 | Prognostic significance of lymphovascular invasion for patients with stage I non-small cell lung cancer |
| Q36421289 | Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. |
| Q36328084 | Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers |
| Q51464905 | Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma. |
| Q36193486 | Prognostic value of metastatic N1 lymph node ratio and angiolymphatic invasion in patients with pathologic stage IIA non-small cell lung cancer |
| Q28396343 | Prognostic value of microRNA expression in operable non-small cell lung cancer patients |
| Q39933893 | Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up |
| Q42365288 | Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy |
| Q28080636 | Progress of Postoperative Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer |
| Q33796191 | Propensity score-matching analysis of postoperative radiotherapy for stage IIIA-N2 non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database |
| Q39470697 | Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer |
| Q37775627 | Prospects for molecular staging of non-small-cell lung cancer from genomic alterations |
| Q90290448 | Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma |
| Q41898033 | Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy |
| Q37347493 | Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial |
| Q37820679 | Quality-of-life concerns in lung cancer patients |
| Q37119462 | Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. |
| Q35552049 | RACK1 is a candidate gene associated with the prognosis of patients with early stage non-small cell lung cancer |
| Q40104941 | RB activity alters checkpoint response and chemosensitivity in lung cancer lines |
| Q44588876 | Racial disparities and survival for nonsmall-cell lung cancer in a large cohort of black and white elderly patients |
| Q42242957 | Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway |
| Q89538218 | Radiotherapy for patients with completely resected pathologic IIIA(N2) non-small-cell lung cancer: a retrospective analysis |
| Q35810510 | Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy |
| Q49058675 | Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. |
| Q37260026 | Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701 |
| Q33404434 | Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study |
| Q33561943 | Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. |
| Q41929429 | Ras oncogene mutations and survival in patients with lung cancer |
| Q37771250 | Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. |
| Q36051678 | Reappraisal of the role of postoperative radiation therapy in patients with pIIIa-N2 non-small cell lung cancer: A propensity score matching analysis |
| Q36709566 | Recent advances in targeted therapy for non-small cell lung cancer. |
| Q36636637 | Recent developments in the chemotherapeutic options for nonsmall cell lung cancer |
| Q99582740 | Recent trends in use of adjuvant chemotherapy in elderly stage II-III non-small cell lung cancer |
| Q44417147 | Recurrence of mediastinal node cancer after lobe-specific systematic nodal dissection for non-small-cell lung cancer |
| Q54998380 | Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies. |
| Q40548969 | Regaining familiarity with own body after treatment for operable lung cancer - a qualitative longitudinal exploration. |
| Q94340591 | Reply: K-Ras: a prognostic factor for survival in non-small cell lung cancer |
| Q37106397 | Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment? |
| Q80100945 | Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors |
| Q33433283 | Revisiting perioperative chemotherapy: the critical importance of targeting residual cancer prior to wound healing |
| Q42290357 | Risk Factors for Nephrotoxicity Associated with Cisplatin. |
| Q36474910 | Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy |
| Q35196367 | Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients |
| Q84568869 | Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer |
| Q42354996 | Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer |
| Q33698439 | Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer |
| Q36768282 | Role of bevacizumab for the treatment of non-small-cell lung cancer |
| Q24633254 | Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data |
| Q51825980 | Role of surgery in clinical N2 non-small-cell lung cancer: a pro and con debate; the 'con' viewpoint. |
| Q46581458 | S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma. |
| Q42848259 | SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. |
| Q27853293 | SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer |
| Q40007032 | SNRFCB: sub-network based random forest classifier for predicting chemotherapy benefit on survival for cancer treatment |
| Q34277248 | SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells |
| Q40406773 | Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages |
| Q47096145 | Saudi lung cancer management guidelines 2017. |
| Q36540398 | Selection for adjuvant chemotherapy in completely resected stage I non-small cell lung cancer: external validation of a Chinese prognostic risk model |
| Q35663412 | Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy |
| Q35008361 | Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress |
| Q27851971 | Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study |
| Q53490063 | Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy. |
| Q36656090 | Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy |
| Q30358684 | Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. |
| Q89973820 | Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study |
| Q46622468 | Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients |
| Q43830793 | Substantial risk affects the stage-dependent outcomes of cisplatin-based adjuvant chemotherapy for completely resected non-small cell lung cancer |
| Q36162509 | Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection |
| Q37226817 | Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis |
| Q26748296 | Surgery versus stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer: less is not more |
| Q33813436 | Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial |
| Q54099068 | Surgical Treatment of Lung Cancer. |
| Q87117284 | Surgical management of lung cancer |
| Q84630409 | Surgical outcome of an anatomical resection of clinical stage IA non-small cell lung cancer assisted with a video-thoracoscopy |
| Q80100820 | Surgical patterns of care in operable lung carcinoma treated with radiation |
| Q38058754 | Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre. |
| Q36482648 | Survival after surgery in stage IA and IB non-small cell lung cancer. |
| Q35104573 | Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study |
| Q38650162 | Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer. |
| Q36349601 | Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study |
| Q63997730 | Survival impact of postoperative therapy modalities according to margin status in non-small cell lung cancer patients in the United States |
| Q42585784 | Survival prediction of stage I lung adenocarcinomas by expression of 10 genes |
| Q33745383 | Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward |
| Q33421361 | Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study |
| Q26865490 | Systemic and targeted therapies for early-stage lung cancer |
| Q84978539 | Systemic treatment of non-small-cell lung cancer |
| Q30833946 | TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer |
| Q37290520 | Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab |
| Q90329563 | Targeting minimal residual disease after surgery with molecular targeted therapy: the real path to a cure? |
| Q49616528 | Targeting minimal residual disease: a path to cure? |
| Q35007976 | Telomere length and recurrence risk after curative resection in patients with early-stage non-small-cell lung cancer: a prospective cohort study |
| Q37158881 | Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer |
| Q36907909 | Ten-year follow-up of a province-wide cohort of surgical lung cancer patients in Nova Scotia. |
| Q30645831 | Test on existence of histology subtype-specific prognostic signatures among early stage lung adenocarcinoma and squamous cell carcinoma patients using a Cox-model based filter |
| Q55277670 | The 3rd Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake. |
| Q93483990 | The 4th Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake |
| Q36119749 | The Globalization of Cooperative Groups |
| Q90598608 | The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells |
| Q37652904 | The Pursuit of Noninvasive Diagnosis of Lung Cancer |
| Q82051566 | The Seventh Tumor, Node, Metastasis Staging System and Lung Cancer Treatment Choices: A Matter of Would, Could, and Should |
| Q30503151 | The ability of LCRMP-1 to promote cancer invasion by enhancing filopodia formation is antagonized by CRMP-1. |
| Q36514569 | The chimeric transcript RUNX1-GLRX5: a biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer |
| Q36742558 | The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada |
| Q64090872 | The economic impact of the transition from branded to generic oncology drugs |
| Q58287526 | The evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model |
| Q37883955 | The evolving role of targeted therapy in early-stage and locally advanced non-small cell lung cancer |
| Q37354111 | The genetics and biology of KRAS in lung cancer |
| Q33905550 | The impact of a novel lung gross dissection protocol on intrapulmonary lymph node retrieval from lung cancer resection specimens. |
| Q86602848 | The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer |
| Q36494147 | The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer |
| Q52980297 | The impact on the prognosis of unsuspected N2 disease in non-small-cell lung cancer: indications for thorough mediastinal staging in the modern era. |
| Q36040638 | The importance of multidisciplinary team management of patients with non-small-cell lung cancer |
| Q37344543 | The influence of the metastasis pattern of mediastinal lymph nodes on the postoperative radiotherapy's efficacy for the IIIA-pN2 non-small-cell lung cancer: a retrospective analysis of 220 patients |
| Q26823305 | The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC) |
| Q36333008 | The potential of proton beam radiation therapy in lung cancer (including mesothelioma). |
| Q41829997 | The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer |
| Q37194315 | The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer |
| Q36854021 | The prognostic significance of multiple station N2 in patients with surgically resected stage IIIA N2 non-small cell lung cancer |
| Q37225452 | The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival |
| Q44365541 | The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database |
| Q34917875 | The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. |
| Q36308285 | The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy |
| Q35667675 | The role of gene expression profiling in early-stage non-small cell lung cancer |
| Q36750080 | The role of induction therapy for resectable non-small cell lung cancer |
| Q37715991 | The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors |
| Q92651060 | The role of postoperative radiotherapy for completely resected pIIIA-N2 non-small cell lung cancer patients with different clinicopathological features: a systemic review and meta-analysis |
| Q33640849 | The role of segmental nodes in the pathological staging of non-small cell lung cancer |
| Q36858192 | The role of surgery in the treatment of stage III non-small-cell lung cancer |
| Q34325455 | The single institutional outcome of postoperative radiotherapy and concurrent chemoradiotherapy in resected non-small cell lung cancer |
| Q96231168 | The top 100 cited articles in lung cancer - a bibliometric analysis |
| Q48592996 | The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF. |
| Q83153095 | The wind of change in the therapy of lung cancer |
| Q38833767 | Therapeutic options following pneumonectomy in non-small cell lung cancer |
| Q37263341 | Thoracoscopic lobectomy for the management of non-small cell lung cancer |
| Q45785709 | Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study |
| Q39034554 | Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials |
| Q34155998 | Time-varying pattern of postoperative recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung cancer (NSCLC): results of a single-center study of 994 Chinese patients |
| Q33743596 | Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer |
| Q47562619 | Toward the individualization of lung cancer therapy |
| Q38632574 | Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization |
| Q37119450 | Treatment and survival differences in older Medicare patients with lung cancer as compared with those who are dually eligible for Medicare and Medicaid |
| Q37755004 | Treatment in resectable, locally advanced NSCLC: which is the best approach? |
| Q88737230 | Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer |
| Q28209997 | Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol |
| Q33521840 | Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase |
| Q36977683 | UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction |
| Q37670699 | UFT and S-1 for treatment of primary lung cancer |
| Q44952449 | Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer |
| Q36429911 | Update in lung cancer 2005. |
| Q36796569 | Update in lung cancer 2006 |
| Q37287067 | Update in lung cancer 2008 |
| Q48326945 | Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. |
| Q53330184 | Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. |
| Q37274628 | VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer |
| Q57025839 | Validation of the 12-gene predictive signature for Adjuvant Chemotherapy Response in Lung Cancer |
| Q64899598 | Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma. |
| Q39951881 | Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials |
| Q37136805 | Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer |
| Q35674874 | Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer |
| Q37720767 | Vinorelbine for non-small cell lung cancer. |
| Q37280912 | Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma. |
| Q38811827 | Wenxia Changfu Formula () induces apoptosis of lung adenocarcinoma in a transplanted tumor model of drug-resistance nude mice |
| Q79383672 | [Adjuvant chemotherapy for stage IB non small cell lung cancer: the standard of care?] |
| Q45955225 | [ERCC1 and RRM1 genes in lung cancer]. |
| Q79487604 | [Evaluation of clinical practice in pulmonary oncology: a review of the literature] |
| Q57456660 | [Expert Consensus on Adjuvant Therapy of Non-small Cell Lung Cancer from China Thoracic Surgeons (2018 Version)] |
| Q83369548 | [Future of chemotherapy] |
| Q79905243 | [Is the current TNM classification still the best criterion for choosing treatment for non-small-cell lung cancer?] |
| Q83970080 | [Lung cancer] |
| Q55471240 | [Multivariate survival analysis of patients with stage I NSCLC]. |
| Q55436083 | [The role of adjuvant chemotherapy in operable non-small cell lung cancer]. |
| Q35940362 | cAMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac |
| Q92580193 | miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients |
Search more.